Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 633

Key brain differences can explain why Ritalin helps improve focus in some more than others

Nearly 16 million American adults have been diagnosed with attention deficit hyperactivity disorder (ADHD), but evidence suggests that more than 30% of them don’t respond well to stimulant medications like Ritalin and Adderall.

A new clinical trial provides a surprising explanation for why this may be the case: There are in how our are wired, including the chemical circuits responsible for memory and concentration, according to a new study co-led by the University of Maryland School of Medicine (UMSOM) and performed at the National Institutes of Health (NIH) Clinical Center.

Our brain cells have different types of chemical receptors that work together to produce optimal performance of brain function. Differences in the balance of these receptors can help explain who is likely to benefit from Ritalin and other stimulant medications. That is the finding of the new research published in the Proceedings of the National Academy of Sciences.

New antibiotics discovery could turn tide against drug-resistant bugs

Lariocidin was efficient against strains of E. coli, including drug-resistant ones, according to the new study.

Researchers say they have discovered a new class of antibiotics that could treat drug-resistant bacteria, the first to reach the market in nearly three decades.

The new molecule, called lariocidin, works by targeting a part of a bacteria’s cell called the ribosome and can disrupt the cell’s functions.

Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow

Atsena Therapeutics has raised $150 million in an oversubscribed series C financing, with hopes that the funds can carry the biotech’s gene therapy designed to reverse or prevent blindness through a potential market approval.

The funding round was led by new investor Bain Capital, with participation from Sofinnova Investments, Abingworth, Wellington Management, Lightstone Ventures, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners and the Manning Family Foundation, according to an April 2 release.

30 Years Younger & Telomere Extension? Could Short Chains of Amino Acids Revolutionize Anti-aging?

Could Short Chains of Amino Acids Revolutionize Anti-aging? We explore the exciting potential of peptide therapy to address key hallmarks of aging, including biological age and telomere length. This video delves into the science behind peptides and examines early clinical findings that suggest significant possibilities for age reversal.

What you’ll learn:
• Key peptides being studied for anti-aging (Epitalon, GHK-Cu, etc.).
• A look at clinical studies and patient data.
• The future of peptide therapy in longevity research.

Credits to : glycanage, dr. luis martinez of clinical peptide society

Please note that the links below are affiliate links, so we receive a small commission when you purchase a product through the links. Thank you for your support!
=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=*=
☑ ProHealth, RENUE, DoNotAge, StemRegen, N1O1, NOVOS ☑ Coupon CODE: REVERSE

Activate Your Stem Cells Naturally — STEMREGEN 15% OFF https://tinyurl.com/StemRelease.

📒Dr Bryan Nitric Oxide Supplement 📒20% OFF Code LAFIRE

Continue reading “30 Years Younger & Telomere Extension? Could Short Chains of Amino Acids Revolutionize Anti-aging?” | >

Cancer cells ‘hacked’ to expose themselves to immune attack

When your social media account starts spewing out nonsensical or threatening status updates, it’s safe to assume that it has been hacked and must be shut down.

The cells in our body also update their “status” by presenting to their environment small proteins that are constantly being produced inside the cell. Our monitors these statuses and destroys cells that produce unusual proteins. A classic example of this is when a cell is infected by a virus and presents parts of the viral proteins on its surface, which allows the immune system to recognize them and destroy the cell.

In contrast, cancer cells often evade detection by displaying very few suspicious proteins that the immune system can identify and target. A new approach to cancer treatment, developed by researchers from Prof. Yardena Samuels’s lab at the Weizmann Institute of Science, increases the number of the immune system’s targets by disrupting production in .

/* */